Nanoencapsulation of Curcumin compounds from Curcuma plants (Curcuma xanthorrhiza) as an anticoagulant therapy in Covid-19 patients

Abstract

Introduction: The COVID-19 is brought about by the SARS-CoV-2 virus (Severe Acute Respiratory Syndrome Coronavirus-2). This pandemic has become a problem in various parts of the world due to the increasing number of positive COVID-19 cases. Severe COVID-19 patients often experience coagulopathy such as thrombosis and venous thromboembolism, which are associated with increased mortality. COVID-19 patients who have coagulopathy have increased D-dimer concentrations, prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT), increased fibrinogen, and thrombocytopenia. The objective of this study is to find an alternative solution for COVID-19 patients who have coagulopathy using the literature review method by searching the data from in vitro, in vivo, and clinical reports by analyzing the potential of the curcumin compound from ginger as an anticoagulant therapy in Covid-19 patients through its thrombosis, platelet, and anti-inflammatory mechanisms. Main Text. The nanoencapsulation of curcumin from Curcuma plants (Curcuma xanthorrhiza) can be an alternative prophylactic anticoagulant for COVID-19 patients. This research uses a qualitative method of conceptual analysis, where the focus of the research is based on pre-existing concepts, which are then understood and developed so that they can be described clearly and can be implemented in the field. The result is curcumin can inhibit the pathways of blood coagulation, so it could be the key to reducing mortality. Conclusion: Nanoencapsulation has proven to be suitable for alternative application in COVID-19 patients considering bioavailability, effectiveness, and minimum side effects.